Vanda Pharmaceuticals (VNDA) Total Current Liabilities (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Total Current Liabilities of $135.6 million in Q1 2026, down 6.6% quarter-over-quarter from $145.2 million in Q4 2025, and up 30.46% year-over-year from $103.9 million in Q1 2025.
Vanda Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $135.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 30.46% year-over-year to $135.6 million; the TTM figure through Mar 2026 stood at $135.6 million (up 30.46% YoY), while the FY2025 annual figure was $145.2 million, up 45.19% from the prior year.
- Total Current Liabilities came in at $135.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $145.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $145.2 million in Q4 2025 to a low of $84.8 million in Q3 2023.
- A 5-year average of $101.0 million and a median of $93.3 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 46.87% in 2022 and dropped 8.41% in 2023, its largest moves.
- Vanda Pharmaceuticals' Total Current Liabilities stood at $91.4 million in 2022, then slipped by 4.09% to $87.7 million in 2023, then rose by 14.01% to $100.0 million in 2024, then jumped by 45.19% to $145.2 million in 2025, then fell by 6.6% to $135.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $135.6 million, $145.2 million, and $117.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 135.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 135.58 Mn |
| Dec 31, 2025 | 145.16 Mn |
| Sep 30, 2025 | 117.87 Mn |
| Jun 30, 2025 | 121.49 Mn |
| Mar 31, 2025 | 103.92 Mn |
| Dec 31, 2024 | 99.98 Mn |
| Sep 30, 2024 | 89.09 Mn |
| Jun 30, 2024 | 93.79 Mn |
| Mar 31, 2024 | 93.34 Mn |
| Dec 31, 2023 | 87.70 Mn |
| Sep 30, 2023 | 84.84 Mn |
| Jun 30, 2023 | 87.40 Mn |
| Mar 31, 2023 | 93.79 Mn |
| Dec 31, 2022 | 91.44 Mn |
| Sep 30, 2022 | 92.62 Mn |
| Jun 30, 2022 | 88.40 Mn |
| Mar 31, 2022 | 90.74 Mn |
| Dec 31, 2021 | 74.42 Mn |
| Sep 30, 2021 | 72.00 Mn |
| Jun 30, 2021 | 71.99 Mn |
| Mar 31, 2021 | 61.78 Mn |
| Dec 31, 2020 | 65.94 Mn |
| Sep 30, 2020 | 61.36 Mn |
| Jun 30, 2020 | 61.59 Mn |
| Mar 31, 2020 | 59.22 Mn |
| Dec 31, 2019 | 59.51 Mn |
| Sep 30, 2019 | 60.00 Mn |
| Jun 30, 2019 | 62.58 Mn |
| Mar 31, 2019 | 59.28 Mn |
| Dec 31, 2018 | 53.02 Mn |
| Sep 30, 2018 | 46.24 Mn |
| Jun 30, 2018 | 46.88 Mn |
| Mar 31, 2018 | 71.96 Mn |
| Dec 31, 2017 | 70.36 Mn |
| Sep 30, 2017 | 71.54 Mn |
| Jun 30, 2017 | 75.44 Mn |
| Mar 31, 2017 | 72.97 Mn |
| Dec 31, 2016 | 50.32 Mn |
| Sep 30, 2016 | 50.68 Mn |
| Jun 30, 2016 | 51.76 Mn |
| Mar 31, 2016 | 55.04 Mn |
| Dec 31, 2015 | 51.32 Mn |
| Sep 30, 2015 | 45.89 Mn |
| Jun 30, 2015 | 45.19 Mn |
| Mar 31, 2015 | 31.79 Mn |
| Dec 31, 2014 | 7.79 Mn |
| Sep 30, 2014 | 38.85 Mn |
| Jun 30, 2014 | 38.29 Mn |
| Mar 31, 2014 | 45.40 Mn |
| Dec 31, 2013 | 32.85 Mn |
| Sep 30, 2013 | 31.91 Mn |
| Jun 30, 2013 | 31.94 Mn |
| Mar 31, 2013 | 31.97 Mn |
| Dec 31, 2012 | 32.26 Mn |
| Sep 30, 2012 | 34.63 Mn |
| Jun 30, 2012 | 34.39 Mn |
| Mar 31, 2012 | 32.66 Mn |
| Dec 31, 2011 | 31.62 Mn |
| Sep 30, 2011 | 33.64 Mn |
| Jun 30, 2011 | 32.86 Mn |
| Dec 31, 2010 | 31.03 Mn |